CN101801342B - 制造阿立哌唑悬浮液和冻干制剂的方法 - Google Patents

制造阿立哌唑悬浮液和冻干制剂的方法 Download PDF

Info

Publication number
CN101801342B
CN101801342B CN2008801007814A CN200880100781A CN101801342B CN 101801342 B CN101801342 B CN 101801342B CN 2008801007814 A CN2008801007814 A CN 2008801007814A CN 200880100781 A CN200880100781 A CN 200880100781A CN 101801342 B CN101801342 B CN 101801342B
Authority
CN
China
Prior art keywords
suspension
aripiprazole
particle size
average particle
sterile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2008801007814A
Other languages
English (en)
Chinese (zh)
Other versions
CN101801342A (zh
Inventor
平冈祥吾
松田贵邦
畑中润一
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39816777&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101801342(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of CN101801342A publication Critical patent/CN101801342A/zh
Application granted granted Critical
Publication of CN101801342B publication Critical patent/CN101801342B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CN2008801007814A 2007-07-31 2008-07-30 制造阿立哌唑悬浮液和冻干制剂的方法 Active CN101801342B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007200088 2007-07-31
JP2007-200088 2007-07-31
PCT/JP2008/064076 WO2009017250A1 (en) 2007-07-31 2008-07-30 Methods for producing aripiprazole suspension and freeze-dried formulation

Publications (2)

Publication Number Publication Date
CN101801342A CN101801342A (zh) 2010-08-11
CN101801342B true CN101801342B (zh) 2012-07-11

Family

ID=39816777

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801007814A Active CN101801342B (zh) 2007-07-31 2008-07-30 制造阿立哌唑悬浮液和冻干制剂的方法

Country Status (27)

Country Link
US (7) US9457026B2 (enExample)
EP (1) EP2170279B1 (enExample)
JP (1) JP4879349B2 (enExample)
KR (1) KR101546106B1 (enExample)
CN (1) CN101801342B (enExample)
AR (2) AR067747A1 (enExample)
CA (1) CA2695178C (enExample)
CO (1) CO6290634A2 (enExample)
CY (1) CY1120165T1 (enExample)
DK (1) DK2170279T3 (enExample)
ES (1) ES2661037T3 (enExample)
HR (1) HRP20180295T1 (enExample)
HU (1) HUE036214T2 (enExample)
IL (2) IL244186A0 (enExample)
LT (1) LT2170279T (enExample)
MX (1) MX2010001311A (enExample)
MY (1) MY152789A (enExample)
NO (1) NO2170279T3 (enExample)
NZ (1) NZ582415A (enExample)
PL (1) PL2170279T3 (enExample)
PT (1) PT2170279T (enExample)
RU (1) RU2483711C2 (enExample)
SI (1) SI2170279T1 (enExample)
TW (1) TWI410255B (enExample)
UA (1) UA97286C2 (enExample)
WO (1) WO2009017250A1 (enExample)
ZA (1) ZA201000307B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2170279T3 (en) * 2007-07-31 2018-03-12 Otsuka Pharma Co Ltd PROCEDURES FOR PREPARING AN ARIPIPRAZOL SUSPENSION AND A FREEZER DRIED FORMULATION
PT105058B (pt) * 2010-04-21 2013-04-17 Hovione Farmaciencia S A Processo para processamento de partículas de ingredientes activos farmacêuticos
RU2535089C2 (ru) * 2010-08-24 2014-12-10 Оцука Фармасьютикал Ко., Лтд. Суспензия и затвердевшая композиция, содержащие производное карбостирила и силиконовое масло и/или производное силиконового масла
JP5980215B2 (ja) * 2011-01-24 2016-08-31 大塚製薬株式会社 アリピプラゾールを有効成分とするケーキ状組成物が含有された医療用器具、及びアリピプラゾールを有効成分とするケーキ状組成物
JO3410B1 (ar) * 2011-06-07 2019-10-20 Otsuka Pharma Co Ltd تركيبة أريبيبرازول مجفف بالتبريد
KR101103011B1 (ko) * 2011-10-13 2012-01-05 (주)일신오토클레이브 스크루 형 고압 발생 장치
CN102524261B (zh) * 2011-12-16 2014-12-03 辽宁师范大学 一种强力生根剂纳米制剂、其制备方法及应用
CN102450269A (zh) * 2011-12-27 2012-05-16 辽宁师范大学 三唑酮纳米胶体悬浮剂及其制备方法
JOP20200109A1 (ar) * 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
JP5341282B1 (ja) * 2012-06-29 2013-11-13 丸石製薬株式会社 アリピプラゾールの経口医薬製剤
US20150174247A1 (en) * 2012-06-29 2015-06-25 Maruishi Pharmaceutical Co., Ltd. Oral pharmaceutical preparation of aripiprazole
JP6007169B2 (ja) * 2012-11-30 2016-10-12 大原薬品工業株式会社 アリピプラゾール無水物を含有する固形製剤の製造方法
US9655951B2 (en) * 2013-01-23 2017-05-23 Cartilast II LLC Preservation of the biological activity of undenatured type II collagen
US9051268B2 (en) 2013-04-30 2015-06-09 Otsuka Pharmaceutical Co., Ltd. Oral solid preparation comprising aripiprazole and method for producing oral solid preparation comprising aripiprazole
EP3233077A4 (en) 2014-12-19 2018-08-08 The Broad Institute Inc. Dopamine d2 receptor ligands
WO2017025930A1 (en) 2015-08-12 2017-02-16 Ftf Pharma Private Limited Oral solution of aripiprazole
CN106474058B (zh) 2015-08-31 2020-01-07 南京诺瑞特医药科技有限公司 具有延长的保质期的阿立哌唑可注射悬浮液制剂
EP3490529A1 (en) 2016-07-28 2019-06-05 Mylan Laboratories Ltd. Process for preparing sterile aripiprazole formulation
US10821200B2 (en) * 2016-12-05 2020-11-03 Hyalo Technologies, LLC Method of sterilization of microparticles
CN108938578A (zh) * 2017-05-25 2018-12-07 万全万特制药（厦门）有限公司 阿立哌唑分散片及其制备方法
WO2021199076A1 (en) * 2020-03-30 2021-10-07 Cipla Limited Injectable aripiprazole formulation
EP4043008A1 (en) 2021-02-15 2022-08-17 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Method for the preparation of a pharmaceutical composition comprising aripiprazole
CN115364049A (zh) * 2021-05-18 2022-11-22 苏州恩华生物医药科技有限公司 一种月桂酰阿立哌唑混悬剂的制备方法
CN115554253B (zh) * 2022-10-14 2024-03-29 浙江圣兆药物科技股份有限公司 一种平稳释药的注射用阿立哌唑冻干制剂及其制备方法
CN117281784B (zh) * 2023-11-24 2024-02-27 山东则正医药技术有限公司 一种阿立哌唑注射剂及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1870980A (zh) * 2003-10-23 2006-11-29 大冢制药株式会社 控释无菌阿立哌唑注射剂和方法
WO2007053904A1 (en) * 2005-11-10 2007-05-18 Alphapharm Pty Ltd Process to control particle size

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB209551A (en) 1922-11-20 1924-01-17 William Mortimer Melmore Improvements in or relating to petrol and other cans
JPS54130587A (en) * 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
CA1209477A (en) 1981-03-26 1986-08-12 Bruce E. Haeger Composition of matter comprising a lyophilized preparation of a penicillin derivative
JPS5832899A (ja) * 1981-08-18 1983-02-25 Takeda Chem Ind Ltd オキセンドロン水性懸濁剤
US4352811A (en) * 1981-11-12 1982-10-05 Hoechst-Roussel Pharmaceuticals Inc. 3-(1-Substituted-4-piperidyl)-1,2-benzisoxazoles
IL68549A (en) * 1983-05-03 1988-05-31 Kit Medidont Ltd Method and instrument for measuring moisture
KR850004274A (ko) * 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
JP2608788B2 (ja) 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
FR2663223B1 (fr) * 1990-06-14 1994-12-02 Af Aplicaciones Far Lab Forme galenique parenterale.
EP0461930B1 (en) * 1990-06-15 1995-09-13 Merck & Co. Inc. A crystallization method to improve crystal structure and size
IT1244880B (it) 1990-12-11 1994-09-12 Torre A Farmaceutici Formulazioni di amminoacidi liofilizzati contenenti glutammina, loro preparazione ed uso nell'alimentazione parenterale
US6193983B1 (en) * 1992-06-01 2001-02-27 The University Of Melbourne Equine herpesvirus glycoproteins
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
CZ293764B6 (cs) * 1993-11-19 2004-07-14 Janssen Pharmaceutica N. V. Farmaceutický prostředek s dostatečným a dlouhodobým uvolňováním léčiva, biodegradovatelné a biokompatibilní mikročástice, způsob jejich výroby a použití
DK0762897T3 (da) 1994-06-02 2003-07-21 Elan Drug Delivery Ltd Fremgangsmåde til forebyggelse af aggregering af proteiner/peptider ved rehydratisering eller optøning
RU2082401C1 (ru) 1994-08-18 1997-06-27 Фармацевтическое акционерное общество "Ферейн" Способ получения лекарственной формы комбинированного препарата
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US6165442A (en) * 1996-02-19 2000-12-26 Nycomed Imaging As Thermally stabilized ultrasound contrast agent
ATE252891T1 (de) 1996-08-26 2003-11-15 Transgene Sa Kationische lipid-nukleinsäure komplexe
US6297231B1 (en) * 1996-10-28 2001-10-02 Merck & Co., Inc. Stabilized carbapenem antibiotic compositions and method of making
GB9705588D0 (en) * 1997-03-18 1997-05-07 Anglia Research Foundation Stable particle in liquid formulations
GB9718986D0 (en) 1997-09-09 1997-11-12 Danbiosyst Uk Controlled release microsphere delivery system
EP1067914B1 (en) * 1998-03-30 2006-02-22 Jagotec Ag Composition and method of preparing microparticles of water-insoluble substances
WO2000006124A2 (en) * 1998-07-30 2000-02-10 Point Biomedical Corporation A novel excipient for the lyophilization of aqueous suspensions of microparticles
DE19857609A1 (de) * 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
US6455526B1 (en) * 1998-12-16 2002-09-24 Aventis Pharmaceuticals, Inc. Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same
US6267989B1 (en) * 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
AU5170400A (en) * 1999-05-27 2000-12-18 George F. El Khoury Topical application of muscarinic and opioid agents for treatment of tinnitus
JP2001187735A (ja) 2000-01-05 2001-07-10 Towa Yakuhin Kk 安定なニコランジル含有粉末の製造法
US6559128B1 (en) * 2000-01-21 2003-05-06 Northwestern University Inhibitors of G protein-mediated signaling, methods of making them, and uses thereof
RU2169574C1 (ru) 2000-01-27 2001-06-27 Кобатов Алексей Иванович Способ получения биопрепарата и сухой биопрепарат
WO2001058428A1 (en) 2000-02-10 2001-08-16 Alkermes Controlled Therapeutics, Inc. Method of preparing a sustained release composition
RU2269339C2 (ru) 2000-03-27 2006-02-10 Дзе Скриппс Рисерч Инститьют Способы ингибирования ангиогенеза и роста опухолей
ES2469642T3 (es) 2000-04-20 2014-06-18 Jagotec Ag Procedimiento mejorado para partículas de fármaco insoluble en agua
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
JP2002241284A (ja) 2001-02-16 2002-08-28 Towa Yakuhin Kk 全身投与用アルガトロバン注射液
MY129350A (en) 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
JP2003063965A (ja) * 2001-06-13 2003-03-05 Otsuka Pharmaceut Factory Inc 注射用シロスタゾール水性製剤
KR100994221B1 (ko) 2001-06-14 2010-11-12 오츠카 세이야쿠 가부시키가이샤 의약 조성물
EP1929998A3 (en) 2001-09-21 2008-11-26 Egalet A/S Controlled release solid dispersions of carvedilol
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
ITMI20020808A1 (it) * 2002-04-17 2003-10-17 Chiesi Farma Spa Procedimento per la preparazione di una sospensione sterile di particelle di beclometasone dipropionato da somministrare per inalazione
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
EP2283864A1 (en) * 2002-07-16 2011-02-16 Elan Pharma International Ltd. Liquid dosage compositions fo stable nanoparticulate active agents
GEP20063996B (en) * 2002-08-20 2006-12-11 Bristol Myers Squibb Co Aripiprazole complex formulation and use thereof
ITMI20022674A1 (it) * 2002-12-18 2004-06-19 Chiesi Farma Spa Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione.
CN1741789A (zh) * 2002-12-31 2006-03-01 尼克塔治疗公司 具有不溶解的活性物质的药物制剂
US7658998B2 (en) 2003-01-22 2010-02-09 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
JP2005022989A (ja) 2003-06-30 2005-01-27 Otsuka Pharmaceut Factory Inc 可溶化または分散化された難溶性化合物を含む組成物
US6987111B2 (en) * 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
US20050032811A1 (en) 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
TWI371274B (en) * 2003-10-23 2012-09-01 Bristol Myers Squibb Co Process for making sterile aripiprazole of desired mean particle size
JP2007509989A (ja) * 2003-10-31 2007-04-19 ポイント バイオメディカル コーポレイション 超音波造影剤として有用な再構成可能なミクロスフィア組成物
WO2005072702A2 (en) 2004-01-20 2005-08-11 Alkermes Controlled Therapeutics, Inc. Method for milling frozen microparticles
BRPI0509184A (pt) * 2004-03-23 2007-09-18 Novartis Ag composições farmacêuticas
DE102005011786A1 (de) * 2005-03-11 2006-09-14 Pharmasol Gmbh Verfahren zur Herstellung ultrafeiner Submicron-Suspensionen
AU2006224759A1 (en) * 2005-03-17 2006-09-21 Synthon B.V. Process of making crystalline Type II aripiprazole
US20070148100A1 (en) * 2005-09-15 2007-06-28 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
US20070148245A1 (en) * 2005-12-22 2007-06-28 Ilan Zalit Compressed solid dosage forms with drugs of low solubility and process for making the same
DK2170279T3 (en) * 2007-07-31 2018-03-12 Otsuka Pharma Co Ltd PROCEDURES FOR PREPARING AN ARIPIPRAZOL SUSPENSION AND A FREEZER DRIED FORMULATION

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1870980A (zh) * 2003-10-23 2006-11-29 大冢制药株式会社 控释无菌阿立哌唑注射剂和方法
WO2007053904A1 (en) * 2005-11-10 2007-05-18 Alphapharm Pty Ltd Process to control particle size

Also Published As

Publication number Publication date
AU2008283251A1 (en) 2009-02-05
CN101801342A (zh) 2010-08-11
PT2170279T (pt) 2018-04-06
AR117941A2 (es) 2021-09-08
US20240139177A1 (en) 2024-05-02
IL244186A0 (en) 2016-04-21
DK2170279T3 (en) 2018-03-12
ES2661037T3 (es) 2018-03-27
US20170035752A1 (en) 2017-02-09
CA2695178A1 (en) 2009-02-05
CO6290634A2 (es) 2011-06-20
RU2009149820A (ru) 2011-09-10
US20210361646A1 (en) 2021-11-25
RU2483711C2 (ru) 2013-06-10
EP2170279A1 (en) 2010-04-07
NO2170279T3 (enExample) 2018-05-26
BRPI0815382A2 (pt) 2015-02-10
KR20100057020A (ko) 2010-05-28
SI2170279T1 (en) 2018-04-30
US20180185358A1 (en) 2018-07-05
TW200922636A (en) 2009-06-01
PL2170279T3 (pl) 2018-05-30
MX2010001311A (es) 2010-04-21
HUE036214T2 (hu) 2018-06-28
JP2010535151A (ja) 2010-11-18
US9457026B2 (en) 2016-10-04
CA2695178C (en) 2015-06-23
US20250302826A1 (en) 2025-10-02
EP2170279B1 (en) 2017-12-27
CY1120165T1 (el) 2018-12-12
US20200246333A1 (en) 2020-08-06
IL244231A0 (en) 2016-04-21
LT2170279T (lt) 2018-03-12
MY152789A (en) 2014-11-28
UA97286C2 (ru) 2012-01-25
HRP20180295T1 (hr) 2018-03-23
JP4879349B2 (ja) 2012-02-22
WO2009017250A1 (en) 2009-02-05
NZ582415A (en) 2012-05-25
AR067747A1 (es) 2009-10-21
US20100196486A1 (en) 2010-08-05
ZA201000307B (en) 2011-04-28
KR101546106B1 (ko) 2015-08-20
TWI410255B (zh) 2013-10-01

Similar Documents

Publication Publication Date Title
CN101801342B (zh) 制造阿立哌唑悬浮液和冻干制剂的方法
US20250064745A1 (en) Freeze-dried aripirazole formulation
CN103917485A (zh) 纳米颗粒制备方法
AU2008283251B2 (en) Methods for producing aripiprazole suspension and freeze-dried formulation
HK1141727A (en) Methods for producing aripiprazole suspension and freeze-dried formulation
HK1141727B (en) Methods for producing aripiprazole suspension and freeze-dried formulation
BRPI0815382B1 (pt) Métodos para a produção de uma suspensão de aripiprazol
BR122019020702B1 (pt) Métodos para a produção de uma formulação liofilizada de hidrato a de aripiprazol, e para a produção de uma formulação liofilizada contendo aripiprazol na forma anidrosa
HK1191245B (en) Freeze-dried aripiprazole formulation
NZ618111B2 (en) Freeze-dried aripiprazole formulation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant